Bilancio 2020, Novartis cresce in fatturato e innovazione - MilanoFinanza.it
Novartis bilancio 2022: andamento del fatturato e della trimestrale
Novartis Annual Report 2021
Novartis Annual Results | Novartis
Novartis: utili e fatturato robusti, ma l'impatto del Covid si fa sentire - MilanoFinanza.it
Novartis, Roche find 'outcome-based' drug pricing an elusive dream | Reuters
Novartis bilancio 2022: andamento del fatturato e della trimestrale
Swiss approve insurance cover for Novartis, Gilead cell therapies | Reuters
Kim Bilancio - President - Greenlayer USA | LinkedIn
Novartis Annual Report 2020
Novartis Annual Report 2020
Claudio Borghi
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors | Journal of Medicinal Chemistry
Novartis Annual Reporting Suite | Novartis
Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. - Abstract - Europe PMC
Novartis taps into gene editing for next generation drugs | Reuters
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuv
Novartis CEO plans 80+ submissions for drug approvals through 2022 | Reuters
Titolo farmaceutico da comprare: Novartis - Proiezioni di Borsa
Cambio ai vertici di Novartis Italia: Valentino Confalone è il nuovo country president - AboutPharma
International Master in Neuroscience's students visit Lek-Novartis | Università degli studi di Trieste
Kim Bilancio - President - Greenlayer USA | LinkedIn
Kim Bilancio - President - Greenlayer USA | LinkedIn
U.S. FDA declines approval of Novartis' cholesterol-lowering drug | Reuters
Risultati finanziari 2021: Novartis triplica l'utile. Roche fatturato in crescita, ma reddito netto cala (-1%) - AboutPharma
Tagli Novartis: la metà dei licenziamenti riguarda dei quadri - Ticinonline
